Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Brose, Marcia
Item TypeName
Concept Proto-Oncogene Proteins p21(ras)
Concept Proto-Oncogene Proteins pp60(c-src)
Concept Proto-Oncogene Proteins c-raf
Concept Proto-Oncogene Proteins B-raf
Concept Proto-Oncogene Proteins c-akt
Concept Proto-Oncogene Proteins c-ret
Academic Article BRAF and RAS mutations in human lung cancer and melanoma.
Academic Article Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
Academic Article Loss of Rap1GAP in papillary thyroid cancer.
Academic Article RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.
Academic Article Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.
Academic Article Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Academic Article Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Academic Article BRAF mutation and thyroid cancer recurrence.
Academic Article Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Academic Article LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer.
Academic Article Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Academic Article Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Academic Article Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.
Academic Article Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Academic Article Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Academic Article Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Academic Article pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Academic Article Reply to C. Bal et al and M. Xing.
Academic Article Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Search Criteria
  • Proto Oncogene Proteins
  • pp60 c src